EP0734264B1 — Compositions that specifically bind to colorectal cancer cells and methods of using the same
Assigned to Thomas Jefferson University · Expires 2004-02-18 · 22y expired
What this patent protects
PCT No. PCT/US94/12232 Sec. 371 Date Apr. 26, 1996 Sec. 102(e) Date Apr. 26, 1996 PCT Filed Oct. 26, 1994 PCT Pub. No. WO95/11694 PCT Pub. Date May 4, 1995Conjugated compounds which comprise an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutic…
USPTO Abstract
PCT No. PCT/US94/12232 Sec. 371 Date Apr. 26, 1996 Sec. 102(e) Date Apr. 26, 1996 PCT Filed Oct. 26, 1994 PCT Pub. No. WO95/11694 PCT Pub. Date May 4, 1995Conjugated compounds which comprise an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive active moiety are disclosed. Methods of treating an individual suspected of suffering from metastasized colorectal cancer are disclosed. Methods of radioimaging metastasized colorectal cancer cells are disclosed. In vitro methods, kits and reagents are disclosed for determining whether or not an individual has metastasized colorectal cancer cells, for determining whether tumor cells are colorectal in origin and for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells.
Drugs covered by this patent
- Trulance (PLECANATIDE) · Salix
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.